Globus Medical Inc (NYSE:GMED) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: September 27, 2016
Having a price of $22.62, Globus Medical Inc (NYSE:GMED) traded 1.66% higher on the day. With the last stock price down -4.78% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. GMED has recorded a 50-day average of $22.93 and a two hundred day average of $23.76. Trade Volume was down over the average, with 635,441 shares of GMED changing hands under the typical 701,952
Zacks Investment Research has downgraded Globus Medical Inc (NYSE:GMED) to Sell in a statement released on 9/28/2016.
On Monday May 16, 2016, Goldman Sachs released a statement about Globus Medical Inc (NYSE:GMED) dropped the target price from $26.00 to $21.00 that suggested a downside of -0.11%.
Recent Performance Chart
Globus Medical Inc has PE ratio of 18.54 with a one year low of $20.48 and a one year high of $28.60 and has a market capitalization of $0.
A total of 9 brokerages have issued a ratings update on Globus Medical Inc. Six brokerages rating the company a strong buy, five brokerages rating the company a buy, one brokerage rating the company a hold, one brokerage rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $29.11.
General Company Details For Globus Medical Inc (NYSE:GMED)
Globus Medical, Inc. is a medical device company. The Company is focused on developing products for patients with musculoskeletal disorders. It is focused on products to treat patients with spine disorders. Its products fall under categories, which include Innovative Fusion and Disruptive Technologies. The Innovative Fusion category products include fusion products to treat spinal disorders for the entire spine, and they can be used in various surgical approaches. The Disruptive Technologies category represents a shift in the treatment of spinal disorders by allowing for surgical procedures and the treatment of spinal disorders. The Company's Disruptive Technology products include motion preservation offerings, such as SECURE-C and SECURE-CR; MONUMENT, an interbody implant for the reduction of a grade 1 spondylolisthesis; KINEX and SIGNIFY bone void fillers, and CONDUCT ceramic-collagen, and SHIELD and AFFIRM products that allow for the treatment of vertebral compression fractures.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.